Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that, despite the...

Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility VANCOUVER, British Columbia, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has completed a prestudy...

Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert...